Table 10. Anamnestic response to a booster dose of Cervarix™ in females seven years after the initial three-dose vaccination series. (129).
| Anti-HPV type 16 | Anti-HPV type 18 | Anti-HPV type 31 | Anti-HPV type 45 | |
|---|---|---|---|---|
| GMT (EL.U/mL) | ||||
| Pre | 720.7 | 502.9 | 209.4 | 192.9 |
| Day 7 | 5894.9 | 3916.2 | 2228.2 | 2530.5 |
| Month 1 | 15 410.7 | 8362.7 | 3630.8 | 4253.8 |
| T-cells (% responders)* | ||||
| Pre | 100 | 96.9 | 95.2 | 95.2 |
| Month 1 | 63.0 | 78.3 | 59.1 | 88.9 |
| B-cells (% responders)** | ||||
| Pre | 100 | 100 | 95.8 | 95.8 |
| Month1 | 77.8 | 45.8 | 45.8 | 74.1 |
* >500 specific CD4 T-cells expressing > 2 of 4 immune markers
**>0 specific memory B-cells per million cells